NCT03930680CompletedPhase 1
Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane
Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane in Patients With Breast Cancer
Source: ClinicalTrials.gov · Last updated 8 Jul 2025
Brief summary (registry, in English)
The purpose of this research study is to determine whether early administration of Dexrazoxane prevents Doxorubicin induced cardiotoxicity.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- First submitted
- 25 Apr 2019
- Start date
- 14 Sept 2021
- Primary completion date
- 11 Jun 2024
- Lead sponsor
- University of Arkansas
- Diseases
- Heart failure
- NCT number
- NCT03930680
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 25
- From 14 Sept 2021 to the primary completion date, 11 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Current illness,
- History of cardiac, or renal disease
Other
- Pregnancy, currently breast feeding
Who the study is looking for
- Women,
- Age 18-65,
- Not pregnant, Not currently breast feeding
- No current illness,
Age in the registry: 18 years to 65 years · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Arkansas for Medical Sciences Coordinator of this site? Confirm its status | Little Rock | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.